Although its predictive use in the context of patients treated with cardiotoxic cancer therapy has been inconsistent, a recent large prospective study of 323 patients observed consistent associations between increased in NT-proBNP and LVEF declines particularly notable in the sequential anthracycline and trastuzumab group (25). The gene discussed is NPPB; the disease is cancer.